Since breast tumor molecular subtype (Luminal A or B, HER2 enriched, and triple negative), is a well-established determinant of differences in patient outcome33, we analyzed receptor expression within molecular subtypes across racial categories. Here, ERBB2 is linked to breast neoplasm.